Hyperprolactinemia and pregnancy: the basic achievements and unresolved problems

Cover Page


From the sociopolitical and economic points of view the child-bearing is very actual problem for Russia. Demographers believe that our population can decrease twice in 25-30 years, because of medical factors partly.Every fifth family in Russia is infertility now. Female infertility is caused by hyperprolactinemia in 25-40 % of all cases. Rate of hyperprolactinemia at the infertile men reaches 30 %. However hyperprolactinemia is the cause of infertility which can be successfully cured now.



Обычный нижний верхний

Full Text



Обычный нижний верхний

About the authors

L K Dzeranova

Endocrinology Research Centre, Moscow, Russia

Author for correspondence.
Email: metabol@endocrincentr.ru

N S Bykanova

Endocrinology Research Centre, Moscow, Russia

Email: metabol@endocrincentr.ru

E A Pigarova

Endocrinology Research Centre, Moscow, Russia

Email: kpigarova@gmail.com


  1. Марова Е И Вакс В В Дзеранова Л К Гиперпролактинемия у женщин и мужчин Пособие для врачей М Pharmacia Upjohn 2000
  2. Дедов И И Мельниченко Г А Романцова Т И Синдром гиперпролактинемии М Тверь Триада, 2004
  3. Романцова Т И Особенности клинической симптоматики диагностики и лечения синдрома гиперпролактинемии у женщин Дисс д ра мед наук М. 2001
  4. Дзеранова Л К Синдром гиперпролактинемии у женщин и мужчин клиника диагностика лечение Дисс д ра мед наук М 2007.
  5. GillamMP MolitchME LombardiG Colao A Advances in the treatment of prolactinomas Endocr Rev 2006 27: 485 534
  6. Casanueva FF, Molitch ME, Schlechte JA et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas Clin Endocrin 2006 65: 265 273.
  7. Webster J, Piscitelli G, Polli A et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea N Engl J Med 1994 331: 904 909.
  8. Swearingen B, Biller BMK. Diagnosis and Management of Pituitary Disorders Humana Press 2008
  9. Casanueva FF Molitch ME Schlechte JA et al Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas Clin Endocrin 2006 65: 265 273
  10. Central Brain Tumor Registry of the United States (CTBRUS). Statistical Report. Primary brain tumors in the US 1997 2001 http://www.cbtrus.org/. Accessed April 8, 2005.
  11. Goluboff LG, Ezrin C Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis J Clin Endocrin Metab 1969 29: 1533 1538.
  12. Scheithauer BW, Sano T, Kovacs KT et al. The pituitary gland in pregnancy. A clinicopathologic and immunohistochemical study of 69 Cases Mayo Clin Proc 1990 65: 461 474.
  13. Rigg LA, Lein A, Yen SSC Pattern of increase in circulating prolactin levels during human gestation Am J Obstet Gyn 1977 129: 454 456.
  14. Gonzalez JG, Elizondo G, Saldivar D et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging Am J Med 1988 85: 217 220.
  15. Elster AD, Sanders TG, Vines FS et al. Size and shape of the pituitary gland during pregnancy and post partum: Measurement with MR imaging Radiology 1991 181: 531 535.
  16. Ricci E, Parazzini F, Motta T et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation Reproduct Toxicol 2002 16:791 793
  17. Ono M, Miki N, Amano K et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas J Clin Endocrin Metab 2010 95: 2672 2679
  18. Molitch ME Pituitary disorders during pregnancy Endocrin Metabol Clin NorthAm2006 35 99 116.
  19. Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Ann Internal Med 1994 121: 473 477.
  20. Molitch ME. Pregnancy and the hyperprolactinemic woman New Engl J Med 1985 312 1364 1370.
  21. Molitch ME Management of prolactinomas during pregnancy J Reprod Med 1999 44(12): 1121 1126
  22. Bronstein MD, Salgado LR, Musolino NR. Medical management of pituitary adenomas: The special case of the pregnant woman Pituitary 2002 5: 99 107.
  23. Moore WT, Eastman RC. Diagnostic Endocrinology. Acromegaly prolactin and gonadotropin secreting ademomas hypopituitaris Philadelphia, Decker 1996
  24. Cohen-Kerem R, Railton C, Orfen D et al. Pregnancy outcome following non-obstetric surgical intervention Am J Surg 2005 190 467 473.
  25. Lebbe M, Hubinont C, Bernard P, Maiter D.Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women Clin Endocrin (Oxf) 2010 73(2):236-42
  26. Davis JR, Farrell WE, Clayton RN. Pituitary tumours Reproduction 2001 121(3): 363-371.
  27. Jeffcoate WJ, Pound N, Sturrock ND et al. Long-term follow-up of patients with hyperprolactinaemia Clin Endocrin 1996 45 299 303.
  28. 28.Divers WA, Yen SSC Prolactin-producing microadenomas in pregnancy Obstet Gyn 1983 62: 425 429.
  29. Krupp P Monka C. Bromocriptine in pregnancy: safety aspects KlinischeWochenschrift 1987 65 823 827.
  30. Krupp P, Monka C, Richter K. The safety aspects of infertility treatments Program of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro, October, 1988.
  31. Robert E, Musatti L, Piscitelli G еt al. Pregnancy outcome after treatment with the ergot derivative, cabergoline Reprod Toxicol 1996 10: 333 337
  32. Colao A, Abs R, Gonzalez Ba rcena Dеt al. Pregnancy outcomes following cabergoline treatment: extended results from a 12- year observational study Clin Endocrin (Oxf) 2008 68(1): 66 71
  33. StalldeckerG Mallea-Gil MS GuitelmanMet al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature Pituitary 2010 13(4): 345-350.
  34. Nybo Andersen AM, Wohlfahrt J, Christens P et al. Maternal age fetal loss: population based register linkage study BMJ2000 320: 1708 1712
  35. Окороков А Н Гиперпролактинемический синдром Диагностика болезней внутренних органов М Мед лит 2001.
  36. Abech DD Moratelli HB Leite SC Oliveira MC. Effects of estrogen replacement therapy on pituitary size, prolactin and thyroid-stimulating hormone concentrations in menopausal women Gyn Endocrin 2005 21(4): 223-236.
  37. Banerjee A, Wynne K, Tan T et al. High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy Clin Endocrin (Oxf) 2009 70(5): 812 813.
  38. Morange I, Barlier A, Pellegrini I et al. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy Eur J Endocrin 1996 135: 413 420.
  39. Molitch ME. Prolactinomas and pregnancy Clin Endocrin 2010 73 147 148



Abstract - 659

PDF (Russian) - 607



Copyright (c) 2017 Dzeranova L.K., Bykanova N.S., Pigarova E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies